Miranda Segrave ‘23 pitched Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on February 20, 2023. Vertex is a biotechnology company founded in 1989. They specialize in developing treatments in areas of high unmet medical need with their core products in Cystic Fibrosis (CF). Miranda’s investment thesis focused on continued demand and a growing market for CF products, a diversified R&D pipeline outside of CF, and a favorable balance sheet with a cash position of over $10 billion. SMIF voted to buy 185 shares of Vertex (VRTX) at market price funded by the sale of 200 shares of the Health Care sector ETF (XLV) and cash in the portfolio.